Lytix Biopharma is a clinical stage pharmaceutical company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. 

Lytix’ product candidate LTX-315 is a first-in-class* oncolytic peptide with the potential to fully personalize immunotherapy. LTX-315 is developed for intratumoral treatment of solid tumors turning cold tumors hot. The phase I/II trial has demonstrated an acceptable and predictable safety profile with promising efficacy signals in monotherapy and combination therapy and the development is proceeding into phase II trials.

LTX-315 turns cold tumors hot by reshaping the tumor microenvironment through an effective release of potent immune stimulating molecules and tumor antigens. Reshaping the tumor microenvironment by LTX-315 triggers the immune system to recognize, infiltrate and attack the cancer cells, opening up the tumor for a variety of combination treatments including the marketed checkpoint inhibitors.

Currently, LTX-315 is developed in combination with adoptive T cell technology for the treatment of soft-tissue sarcoma, an unmet medical need and potential orphan drug designation. Development of LTX-315 in combination with checkpoint inhibitors for the treatment of metastatic malignant melanoma and other indications is in planning.

LTX-315 is a promising drug candidate with the potential to fully personalize immunotherapy by its mode of action to use the patient’s own tumor as its own vaccine, expose the immune system to one patient’s own cancer antigens, and to generate patient specific antitumor immunity. LTX-315 will convert cancers that are not recognized by the immune system and that are immunologically cold and unresponsive to immune therapy (the majority of cancers) to immunologically hot and, as a result, responsive to combination therapies with checkpoint inhibitors. LTX-315 has the potential to be used across several cancer indications, in various stages of cancer (early versus advanced), in combination with, or after, current standard of care therapy, primarily in combination with other immune therapies like checkpoint inhibitors or with chemotherapies.


* ’’First-in-class’’ refers to a pharmaceutical which often has a new mechanism of action which differs from existing therapies, FDA Novel Drugs Summary, 2016.

 

For more information, please email us at: post@lytixbiopharma.com


Top 20 shareholders of Lytix Biopharma AS - as of August 2018
Shareholder Number of shares % of shares
TAJ Holding AS 3 668 291 16.3
North Murray AS* 2 222 463 9.9
3 T PRODUKTER 1 725 431 7.7
CARE Holding AS* 1 608 080 7.1
Picasso Kapital AS 1 122 860 5.0
Jakob Hatteland Holding AS 1 000 000 4.4
Brødrene Karlsen Holding AS 709 273 3.2
Rothesay Limited 685 184 3.0
Mikael Lönn 616 967 2.7
Lysnes Invest AS* 580 973 2.6
Norinnova Invest AS 557 510 2.5
Per Strand Eiendom AS 496 350 2.2
Hopen Invest AS* 457 363 2.0
LMK Forward AB 346 000 1.5
Jahatt AS 250 000 1.1
Kreftforeningen 218 000 1.0
Frewi AS 200 010 0.9
Harila Invest AS 192 680 0.9
4LB Invest AS 160 040 0.7
Norinnova Technology Transfer AS 155 790 0.7
Other shareholders 5 520 519 24.5
Total 22 493 784
100.0

*Members of the board and/or management of Lytix Biopharma ASA are represented.

 

* List of insiders within the Board and Management
Lytix Biopharma Board Lytix Biopharma Management
Espen Johnsen, Chairman Edwin Klumper, CEO
Gert W. Munthe Gjest Breistein
Debasish Roychowdhury Hamina Patel
Bernt Endrerud Øystein Rekdal